Bruce Main

The True Currency is Energy - SpaceX/xAI/Tesla youtube.com/shorts/BcOL7Yj…. @stoffie54 @

⛱️🌊 Just another day in the City of Johannesburg. Let’s get Joburg working. Register to #VoteDA. Visit check.da.org.za.

🤣 At this point I want to register to vote in Johannesburg

Lot of great gags in this movie 😂

Solving Rubik’s Cubes, while juggling them.

$IBRX @DrPatrick #Anktiva

The excitement of using #nk cells to kill #cancer is reaching a critical mass. Nature paper showing CAR-NK can kill solid tumors if transfected with an olfactory gene... OR7A10 $IBRX has FDA approval for the most potent NK activator known to man #ANKTIVA nature.com/articles/s4158…

Electricity output is the single best proxy for industrial capacity

$IBRX I already shared a bunch of clips now here the full Cuomo show with @DrPatrick that was just released Special Edition: Why Can’t We Cure Cancer? A National Conversation youtu.be/L6gbF1kuHiQ

Met @DrJBhattacharya who heads NIH and @DrTonyLetai who heads NCI for the first time. The joy of a deep conversation between true scientists and doctors whose life’s mission is to help our patients and the American people is evident! I truly enjoyed discussing the science underlying our work on IL-15 and the decade of trials we undertook since 2015 in partnership with NCI. Credit to the NCI for identifying IL-15 as the number one ranked cytokine to cure cancer… the report on the table which I shared with these 2 leaders of science was such an open and collaborative discussion. More of such meetings should happen! Science is the true north.

Thank you @ChrisCuomo for keeping the spotlight on this critical fight against cancer, which has devastated so many lives. My husband was diagnosed with glioblastoma and given just 12 months to live. We fought hard to get him into Dr. Patrick Soon-Shiong’s clinic. He’s now on #ANKTIVA and PD-L1 NK cell infusions—his latest brain scan is NORMAL! This treatment needs to be available to ALL cancer patients nationwide—stop slow-walking it, @FDA! Dr. Pat holds the key; let’s unlock it for everyone. Grateful for sharing this story. #Immunotherapy @POTUS

$IBRX oh my god, PLEASE you gotta watch this: On the Cuomo show last night with @drpatrick as a guest, an ex-FDA exec basically spilled everything: Total CONFIRMATION of the CHAOTIC MESS INSIDE the FDA and how deep BIG PHARMA’S INFLUENCE really runs. Uncoordinated and bureaucratic is still an understatement — it’s practically by design at this point. And then there’s the bit about Merck and why Keytruda got approved… fascinating, if not a little too telling: “Multibillion dollar company with floors of people that understand the science in very subtle ways and what the most direct streamline path will be to get an FDA novel.” Admittedly there’s supposedly a new way of thinking now within the FDA - the talk of “collaboration,” “accelerated approvals,” etc. But, also, in this round it’s confirmed: real change will still take a while. Meanwhile, patients are still running out of time - this program made that painfully clear (see tweets of patients reports)

Will be an important discussion. Live event. Please listen in. NewsNation

Huge shoutout to Chris Hitchings @stoffie54 for throwing an absolute banger event on AI ruling the new marketing jungle! @MichaelJordaan unpacked the importance of the science behind the data, forging a marketing accelerator that hurls you into a centrifuge of wild further sales madness! Cherry on top: @RassieRugby , Springbok coach building a legendary brand Go Bokke! 🔥🤣

ImmunityBio $IBRX three-year strategy outlined 👇

Evidence as far back as a decade ago that the tumor itself shape shifts in response to chemo! We need to anticipate these moves ahead of time to counter them... chess instead of checkers. That's the paradigm change of Quantum Oncotherapeutics and Immunotherapy 2.0 nature.com/articles/ncomm…

My mom died of #cancer #anktiva could have saved her $IBRX

Here is the mind map that I deconstructed for the audience at the Milken /Nixon summit today. So glad that Carl June and Jim Allyson were in the audience !! This was the first time in 10 years that I presented our work to explain this map I drew in Jan 2016. It was fun to unveil our hypothesis and the validation for the first time ( and I am not sure if it surprised a lot of people!) and reveal the decade of work that has gone into proving the hypothesis that a paradigm change is need..Lymphopenia matters and now we can treat it! The tumor itself shift shapes while at the same time the immune cells do the same in response..enormous complexity of quantum change, but we have now figured how to dance with that quantum music and outsmart the disease! Enjoy the AI podcast of a portion of this mind map..it took about half of this drawing. Next time I will dictate the rest

$IBRX by @DrPatrick S9:E4 - Hidden in Plain Sight. Just a Number What was missing was a $10 blood test. Absolute lymphocyte count - ALC. On every CBC panel in every hospital. Normal range: 2,000 to 4,000. Below 1,500, you're lymphopenic. Below 500, your hazard ratio for early death jumps 200% across all tumor types. One in five Americans - 52 million people - have lymphopenia. Chemo causes it. Radiation causes it. Aging causes it. Oncologists see the number every day and do nothing about it. PSS told the room he went to the FDA. Tried to convince them lymphopenia was the missing link - why patients fail immunotherapy, why survival curves flatten. The FDA's response: "Well, that's just a number." His reply: "Hemoglobin is a number. PO2 is a number. Blood sugar is a number. ALC is a number. But what's the consequence of this number?" Lymphopenia reduces survival across all tumor types. IL-15 reverses it. IL-15 was ranked number one. "That's logic to me." One country's regulators listened.

$IBRX developed the first AI-controlled robot that can extract natural killer cells, cutting costs by 10x. Journalist in awe, nails it: “It’s embarrassing to me as an American 🇺🇸 that we had this first and the Saudis 🇸🇦are gonna bring it to market in a much better way”

$IBRX- The video of Dr. Patrick Soon-Shiong is a "thesis defense" for the Lymphocyte-Stimulating Agent (LSA) class. Here is the highly detailed, data-backed analysis. Most people think of $IBRX as a "bladder cancer stock." The reality? We are witnessing the birth of a new backbone for all of oncology. video.twimg.com/amplify_video/… 1. The Molecular Architecture: IL-15N72D Superagonist Standard IL-15 has a short half-life (<40 mins) and limited efficacy. ANKTIVA (N-803) is a fusion complex consisting of an IL-15 mutant (N72D) and an IL-15 receptor alpha-Fc fusion protein. The "Super" Factor: The N72D mutation increases binding affinity to the IL-2/15 receptor 5-fold. Persistence: The Fc-fusion extends the half-life to 25 hours, allowing the drug to accumulate in lymphoid tissues where the real "immune training" happens. 2. The "ALC 1.2" Threshold: A New Clinical Biomarker The most critical takeaway from the recent Lung Cancer data (QUILT-3.055) is the Absolute Lymphocyte Count (ALC). The Metric: Patients who maintained an ALC ≥1.2 x 10³ cells/µL demonstrated a median Overall Survival (OS) of 21.1 months. Why it Matters: This nearly triples the historical 7-9 month OS seen with standard chemotherapy. ANKTIVA isn't just killing cancer; it's fixing the "Immune Exhaustion" (lymphopenia) caused by prior failed treatments. 3. Reversing PD-1 Failure: The "Brakes vs. Engine" Logic Checkpoint inhibitors (PD-1/L1) work by "taking the brakes off" the immune system. But if a patient is lymphopenic, there is no engine to drive. The Synergy: ANKTIVA upregulates PD-L1 expression on immune cells, making the cancer more visible to checkpoint inhibitors while simultaneously proliferating the killer cells needed to do the work. Innate + Adaptive: It activates NK cells for the immediate strike and Memory T-cells for long-term protection, ensuring the cancer doesn't return (durable response). The Final Conclusion: The "Security System" Upgrade Most cancer treatments are like "Sledgehammers" (Chemo). They smash the cancer, but they also smash the patient. Other modern drugs are like "Brakes" (Checkpoints). They try to stop the cancer from hiding, but if the patient's immune system is already exhausted, there’s no "engine" to drive the cure. ANKTIVA is the "Super-Engine." It doesn't just attack cancer; it "trains" your own Natural Killer (NK) cells and T-cells to recognize the enemy. The Memory: Once trained, your body remembers how to fight that specific cancer. This is why we see patients staying healthy for years, not just months. It’s like a permanent security system upgrade for your body. The Universal Key: Because this works by boosting the body, not just attacking one specific type of tumor, it can potentially work for Lung, Bladder, Colon, and Breast cancers. The Bottom Line for Investors: We are seeing 700% revenue growth because the world is realizing that "Orchestrating" the immune system is better than "Smashing" the body. With a 40% short interest and 100% utilization, the market is currently a "coiled spring." As the science becomes undeniable, the valuation has no choice but to follow. WE ARE JUST GETTING STARTED. WATCH THE VIDEO. IT IS REALLY WORTHWHILE . PSS IS ON FIRE